Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study

By sjmartinez • October 30, 2023

Kudo M, Finn RS, Cheng AL, Zhu AX, Ducreux M, Galle PR, Sakamoto N, Kato N, Nakano M, Jia J, Vogel A. Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study. Liver Cancer. 2023 Mar 4;12(5):479-493. doi: 10.1159/000529996. PMID: 37901766; PMCID: PMC10601852.

Tags: Albumin-bilirubin grade, Atezolizumab, Bevacizumab, Hematology/Oncology, Publications, Unresectable hepatocellular carcinoma

Patient-reported quality of life and adherence outcomes after integrating exclusive liquid meal replacement in patients with head and neck cancer undergoing chemoradiation: results from a phase II study

Valle LF, Chu FI, Wang X, Erman A, Hernandez J, Kaoh E, Edgar N, Raldow AC, Wong DJ, Steinberg ML, Kishan AU, Chin RK, Hegde[...]

Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial

Cardoso F, O'Shaughnessy J, Liu Z, McArthur H, Schmid P, Cortes J, Harbeck N, Telli ML, Cescon DW, Fasching PA, Shao Z, Loirat D, Park[...]

Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors

Khan SH, Choi Y, Veena M, Lee JK, Shin DS. Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors.[...]